References
- The Familial Hypercholestrolemia Foundation Available from: https://thefhfoundation.org/heterozygous-vs-homozygous-fhAccessed May 12, 2017
- StoneNJRobinsonJGLichtensteinAHACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol201320146328892934
- ReinerŽManagement of patients with familial hypercholesterolaemiaNat Rev Cardiol2015121056526076948
- ImićIReinerŽAdverse effects of statins – myths and realityCurr Pharm Des20152191220122625312733
- ReinerZResistance and intolerance to statinsNutr Metab Cardiovasc Dis201424101057106624996502
- DaduRTBallantyneCMLipid lowering with PCSK9 inhibitorsNat Rev Cardiol2014111056357524958078
- KaralisDGVictorBAhedorLLiuLUse of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patientsCholesterol2012201217
- LeporNEKereiakesDJThe PCSK9 inhibitors: a novel therapeutic target enters clinical practiceAm Health Drug Benefits20158948348826834934
- LiCLinLZhangWEfficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trialsJ Am Heart Assoc201546e00193726077586
- PećinIHartgersMLHovinghGKDentRReinerŽPrevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitorsEur J Prev Cardiol201724131383140128644091
- ReinerŽPCSK9 inhibitors in clinical practice: expectations and realityAtherosclerosis201827018718829366497
- Repatha prescribing information Available from: http://pi.amgen.com/united_states/repatha/repatha_pi_hcp_english.pdfAccessed August 23, 2017
- Praluent prescribing information Available from: http://products.sanofi.us/praluent/praluent.pdfAccessed August 23, 2017
- SabatineMSGiuglianoRPKeechACEvolocumab and clinical outcomes in patients with cardiovascular diseaseN Engl J Med2017376181713172228304224
- ZhangXLZhuQQZhuLSafety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trialsBMC Med20151312326099511
- RobinsonJGFarnierMKrempfMEfficacy and safety of alirocumab in reducing lipids and cardiovascular eventsN Engl J Med2015372161489149925773378
- BlomDJHalaTBologneseMA 52-week placebo-controlled trial of evolocumab in hyperlipidemiaN Engl J Med2014370191809181924678979
- SchwartzGGBessacLBerdanLGEffect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trialAm Heart J2014168568268925440796
- HessGPNatarajanPFaridiKFFievitzAValsdottirLYehRWProprotein convertase subtilisin/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribingCirculation2017136232210221929084735
- FoodyJMJoyceATRudolphAELiuLZBennerJSPersistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care studyCurr Med Res Opin20082471987200018554430
- SaborowskiMDölleMMannsMPLeitolfHZenderSLipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: effectiveness, therapy adherence and safety in a real world cohortCardiol J2018251324129168543